The launch of the first drugs to inhibit the cancer-related protein KRAS was a milestone moment in oncology, but their efficacy wanes over time and tumours can develop res
As the industry has transitioned much of its R&D expertise into large molecule therapies, an emerging approach could provide a revolutionary treatment tool.
There is plenty of evidence that next-generation sequencing (NGS) for lung cancer can improve patient outcomes and save healthcare systems money, but access across Europe
